BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27137427)

  • 1. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
    Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
    J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.
    Maller JJ; Broadhouse K; Rush AJ; Gordon E; Koslow S; Grieve SM
    Mol Psychiatry; 2018 Aug; 23(8):1737-1744. PubMed ID: 29133948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder.
    Korgaonkar MS; Rekshan W; Gordon E; Rush AJ; Williams LM; Blasey C; Grieve SM
    EBioMedicine; 2015 Jan; 2(1):37-45. PubMed ID: 26137532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.
    Etkin A; Patenaude B; Song YJ; Usherwood T; Rekshan W; Schatzberg AF; Rush AJ; Williams LM
    Neuropsychopharmacology; 2015 May; 40(6):1332-42. PubMed ID: 25547711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial.
    Grieve SM; Korgaonkar MS; Etkin A; Harris A; Koslow SH; Wisniewski S; Schatzberg AF; Nemeroff CB; Gordon E; Williams LM
    Trials; 2013 Jul; 14():224. PubMed ID: 23866851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder.
    Korgaonkar MS; Williams LM; Song YJ; Usherwood T; Grieve SM
    Br J Psychiatry; 2014 Oct; 205(4):321-8. PubMed ID: 24970773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
    Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
    Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial.
    Tadić A; Wachtlin D; Berger M; Braus DF; van Calker D; Dahmen N; Dreimüller N; Engel A; Gorbulev S; Helmreich I; Kaiser AK; Kronfeld K; Schlicht KF; Tüscher O; Wagner S; Hiemke C; Lieb K
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):705-16. PubMed ID: 26899588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
    Buchalter ELF; Oughli HA; Lenze EJ; Dixon D; Miller JP; Blumberger DM; Karp JF; Reynolds CF; Mulsant BH
    J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
    van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
    Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
    J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
    Kircanski K; Williams LM; Gotlib IH
    Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder.
    Korgaonkar MS; Goldstein-Piekarski AN; Fornito A; Williams LM
    Mol Psychiatry; 2020 Jul; 25(7):1537-1549. PubMed ID: 31695168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.